Sector News

Abbott, Mylan back generics deal, tweak terms after tax rule change

October 22, 2014
Life sciences
(Reuters) – Abbott Laboratories and Mylan Inc on Wednesday said they would go ahead with their $5.3 billion deal in which Mylan will buy part of Abbott’s overseas generics business and set up headquarters in the Netherlands, but they tweaked the terms of the transaction.
The move comes after the U.S. Treasury on Sept. 22 made changes to the corporate tax rules that govern such “inversion” merger deals, in which companies move their operations to countries with lower taxes than in the United States. The new rules raise the bar for this tax treatment and also make it harder to reap other tax benefits of an inversion.
About ten U.S. companies had deals in the works when the Treasury changed the rules. Some, including Salix Pharmaceuticals and former Abbott business Abbvie, pulled out of their own inversion-based deals, while others decided to go forward with their deals.
Investors and analysts were not certain where Abbott and Mylan would fall.
“The positive takeaway is that Abbott still plans to close its deal with Mylan in the first quarter of 2015, despite the pressure on inversions from the U.S. Treasury, and some walking away by other companies from inversions,” said Jeff Windau, an analyst with Edward Jones. “The (tax law) changes from Treasury are making people re-look at deal terms, and deals are not as favorable now. That’s what happened here, there had to be some tweaks.”
Abbott plans to sell to Mylan its generics business in developed markets outside the United States. It plans to keep its generic brands in fast-growing emerging markets.
Mylan said that the terms of the deal were changed to include better pricing terms for Mylan at Abbott units that will manufacture and supply products for Mylan. It also said that Mylan will issue 110 million shares in the newly formed company to Abbott, 5 million more than the original terms dictated.
Mylan shareholders will own 78 percent of the company and Abbott will own 22 percent of the new company. Mylan said the deal would be accretive.
Abbott has said it plans to quickly sell the shares after the closing of the deal. (Reportingby Caroline Humer and Ransdell Pierson; Editing by Chizu Nomiyama)

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]